Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Investors & Media
  • Contact
    Top Links
    • Investors & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Scientific Publications
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 – AML
      • Tipifarnib Clinical Trials
      • AIM-HN – HNSCC
      • KURRENT-HN – HNSCC
      • KURRENT-LUNG
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Investors & Media
    • Contact
    • MenuMenu

    Analyst Coverage

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Firm Analyst
    Barclays
    Peter Lawson, DPhil (Oxon)
    Brookline Capital Markets
    Leah Cann
    Cantor Fitzgerald
    Li Watsek
    Cowen and Company
    Phil Nadeau, Ph.D.
    Credit Suisse
    Tiago Fauth
    H.C. Wainwright & Co.
    Joseph Pantginis, Ph.D.
    Jefferies
    Roger Song, M.D., CFA
    JMP Securities
    Reni Benjamin, Ph.D.
    Stifel
    Brad Canino
    SVB Securities
    Jonathan Chang, Ph.D., CFA
    Wedbush
    Robert Driscoll, Ph.D.

    Kura Oncology, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Kura Oncology, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kura Oncology, Inc. or its management. Kura Oncology, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
    Footer Links - Investors
    • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top